Evidence map›Paper›PMID 33794223›Full record

ArticleJournal of immunological methods2021

Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds.

Peter Canning, Carole Bataille, Nicolas Bery, Sabine Milhas, Angela Hayes, Florence Raynaud, Ami Miller, Terry Rabbitts

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunological methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Antibody-Based Approaches to Target Pancreatic Tumours.Antibodies (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Peter CanningWeatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Carole BatailleChemistry Research Laboratory, 12 Mansfield Rd, Oxford OX1 3TA, UK.
Nicolas BeryWeatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Sabine MilhasWeatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Angela HayesInstitute of Cancer Research, 15 Cotswold Road, Sutton, London SM2 5NG, UK.
Florence RaynaudInstitute of Cancer Research, 15 Cotswold Road, Sutton, London SM2 5NG, UK.
Ami MillerWeatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK; Institute of Cancer Research, 15 Cotswold Road, Sutton, London SM2 5NG, UK.
Terry RabbittsWeatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK; Institute of Cancer Research, 15 Cotswold Road, Sutton, London SM2 5NG, UK. Electronic address: terry.rabbitts@icr.ac.uk.
John Radcliffe Hospital · GBInstitute of Cancer Research · GBOxford Research Group · GB

Funding

Cancer Research UK 22897Medical Research Council MR/J000612/1
6 · The paper itself

Abstract

The use of intracellular antibodies as templates to derive surrogate compounds is an important objective because intracellular antibodies can be employed initially for target validation in pre-clinical assays and subsequently employed in compound library screens. LMO2 is a T cell oncogenic protein activated in the majority of T cell acute leukaemias. We have used an inhibitory intracellular antibody fragment as a competitor in a small molecule library screen using competitive surface plasmon resonance (cSPR) to identify compounds that bind to LMO2. We selected four compounds that bind to LMO2 but not when the anti-LMO2 intracellular antibody fragment is bound to it. These findings further illustrate the value of intracellular antibodies in the initial stages of drug discovery campaigns and more generally antibodies, or antibody fragments, can be the starting point for chemical compound development as surrogates of the antibody combining site.

Indexed as

Adaptor Proteins, Signal TransducingAntibodiesAntigens, NeoplasmBinding, CompetitiveCells, CulturedDrug DiscoveryHumansImmunoglobulin FragmentsIntracellular SpaceLeukemia, T-CellLIM Domain ProteinsProtein ConformationProto-Oncogene ProteinsSmall Molecule LibrariesSurface Plasmon ResonanceT-Cell Acute Lymphocytic Leukemia Protein 1Adaptor Proteins, Signal TransducingAntibodiesAntigens, NeoplasmImmunoglobulin FragmentsLIM Domain ProteinsLMO2 protein, humanProto-Oncogene ProteinsSmall Molecule LibrariesTAL1 protein, humanT-Cell Acute Lymphocytic Leukemia Protein 1Abd compoundsChromosomal translocationsDrug discoveryGATAIntracellular antibodiesLeukaemiaLMO2SPRTAL1/SCL

Identifiers

PMID33794223
PMCPMC8208243
OpenAlexW3141356292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.